key: cord-0904374-sogah0wn
authors: Kumar, Deepak; Singh, Sukhpreet; Yadav, Deepak; Kaur, Sumanpreet; Kumari, Monu; Jain, Samiksha; Bhattacharyya, Rajasri; Banerjee, Dibyajyoti
title: Prediction of remdesivir resistance in COVID-19 illness: Need for development of clinical laboratory test
date: 2021-06-10
journal: Indian J Clin Biochem
DOI: 10.1007/s12291-021-00987-w
sha: fff6bbe9c980a69ad4cca02b70831470d265f6fd
doc_id: 904374
cord_uid: sogah0wn

nan

Remdesivir is thought to be effective for certain groups of patients suffering from COVID-19 illness. Currently, FDA has approved it for the purpose and WHO has issued a conditional recommendation for its use. Some evidence has been gathered in favor of its use, but data from large scale clinical trials are expected to give more insight into the matter [1] .

At the present moment, molecular understanding regarding the use of remdesivir in SARS-CoV2 infected patients (COVID-19 disease) is scanty. Remdesivir is a nucleotide analogue that inhibits RNA dependent RNA polymerase (RdRp) of the virus. In case the binding site of the drug is mutated, remdesivir may not fit in the active site for the desired effect. It is in this context, we have docked remdesivir at the binding site of wild type RdRp bound template primer RNA complex (please see supplimentary). The remdesivir was observed to fitted there with binding energy -8.68 kcal/mol. The reported interacting residues (R555, V557, D618, T680, N691, D760 and D761) are in contact with remdesivir ring and are shown in Fig. 1a [2] . The nucleoside homolog ring faces towards the primertemplate implying inhibition of elongation of viral RNA.

The most negative binding energy obtained in mutant cases (R555, V557, D618, T680, N691, D760, D761) were -8.93, -8.42, -6.55, -7.65, -7.42, -8.70, -8.26, respectively. In the mutant cases, remdesivir binding is shifted from the actual elongation site. However, in R555A and D760A mutant cases, the binding energy was observed to be more negative ( 8.93 and 8.70 kcal/mol, respectively). In Fig. 1b , remdesivir binding with D760 mutant RdRp with template primer is shown.

We have observed that if any of the above-mentioned interacting residues are mutated, then remdesivir binding position is changed. So, in case of mutated RdRp, remdesivir may not stop the viral RNA elongation and the virus may acquire drug resistance. In SARS-COV2 virus, mutation near the binding sites (putative docking site of remdesivir in RdRp) is found [3] . However, it causes remdesivir resistance or not is currently unknown [4] . There are views that the remdesivir resistant strain cannot survive [5] . We believe that at the current moment it is impossible to comment with certainty that remdesivir resistant strain will cause a fatal COVID-19 disease or not and more focussed research should be dedicated in the concerned field. For stepping towards such direction, we must amplify the critical viral regions and sequence it for understanding the emergence of remdesivir resistant SARS-CoV2 strain.

The online version contains supplementary material available at https://doi.org/10.1007/s12291-021-00987-w.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. 

Remdesivir for COVID-19 in Europe: will it provide value for money?

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Potential Inhibitors Targeting RNA-Dependent RNA Polymerase Activity (NSP12) of SARS-CoV-2. 2020

Remdesivir failure with SARS-CoV-2 RNAdependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19

Remdesivir against COVID-19 and Other Viral Diseases